NCT05228106View on ClinicalTrials.gov

68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Solid Cancers
Interventions
DIAGNOSTIC_TEST

[68Ga]-PSMA-617

The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.

Trial Locations (1)

J1H5N4

RECRUITING

CHUS, Sherbrooke

All Listed Sponsors
lead

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

OTHER